We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

75 hedge funds and large institutions have $176M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
1.32%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
75
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.7M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.3M
3
FCM
Farallon Capital Management
California
+$10.3M
4
JCM
JS Capital Management
New York
+$10.3M
5
PHS
PFM Health Sciences
California
+$10.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$17M +$17.7M +1,710,855 New
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$9.96M +$10.3M +1,000,000 New
FCM
3
Farallon Capital Management
California
$9.96M +$10.3M +1,000,000 New
JCM
4
JS Capital Management
New York
$9.96M +$10.3M +1,000,000 New
PHS
5
PFM Health Sciences
California
$9.96M +$10.3M +1,000,000 New
RCM
6
RA Capital Management
Massachusetts
$9.96M +$10.3M +1,000,000 New
GCL
7
Glazer Capital LLC
New York
$8.89M +$9.23M +892,997 New
SRCM
8
Sage Rock Capital Management
New York
$8.22M +$8.54M +825,618 New
Citadel Advisors
9
Citadel Advisors
Florida
$7.19M +$7.46M +721,766 New
FCMV
10
Foresite Capital Management V
California
$6M +$6.23M +602,500 New
MAMNY
11
Marathon Asset Management (New York)
New York
$5.78M +$6M +580,000 New
C
12
Chescapmanager
Maryland
$4.86M +$5.04M +487,700 New
Millennium Management
13
Millennium Management
New York
$4.73M +$4.91M +475,000 New
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$4.48M +$4.65M +450,000 New
Franklin Resources
15
Franklin Resources
California
$3.98M +$4.14M +400,000 New
HMC
16
Harvard Management Company
Massachusetts
$3.98M +$4.14M +400,000 New
SCM
17
Suvretta Capital Management
New York
$3.98M +$4.14M +400,000 New
HM
18
HealthCor Management
New York
$3.49M +$3.62M +350,000 New
ACA
19
Arena Capital Advisors
California
$3.29M +$3.42M +330,617 New
DCM
20
DAFNA Capital Management
California
$2.99M +$3.1M +300,000 New
LGM
21
Logos Global Management
California
$2.99M +$3.1M +300,000 New
RSCM
22
Rock Springs Capital Management
Maryland
$2.08M +$2.16M +209,332 New
WP
23
Woodline Partners
California
$2.07M +$2.15M +207,674 New
ACM
24
Altium Capital Management
New York
$1.99M +$2.07M +200,000 New
SC
25
Sculptor Capital
New York
$1.69M +$1.76M +170,000 New
1
2 3

PRDS Hedge Fund Activity: Q1 2021 in Review

75 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q1 2021, worth a combined $176M.

Buyers outnumbered sellers: 75 funds opened new PRDS positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $17.7M.

  • 75 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $176M of Pardes Biosciences, Inc. Common Stock stock for Q1 2021.
  • 75 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +75 holders.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q1 2021 was T. Rowe Price Associates, an estimated $17.7M added.

Based on aggregated 13F filings for Q1 2021.